Senhwa Biosciences Presents Clinical Data Abstract on Pidnarulex at 2024 ESMO Congress
Pidnarulex (CX-5461) showed acceptable tolerability and preliminary efficacy in Phase Ib study, with 40% of evaluable end-stage oncology patients achieving clinical benefit, including stable disease (SD) in those previously resistant to PARP inhibitors.
Highlighted Terms
Related News
Senhwa Biosciences Presents Clinical Data Abstract on Pidnarulex at 2024 ESMO Congress
Pidnarulex (CX-5461) showed acceptable tolerability and preliminary efficacy in Phase Ib study, with 40% of evaluable end-stage oncology patients achieving clinical benefit, including stable disease (SD) in those previously resistant to PARP inhibitors.